End-stage renal disease (ESRD) undergoing hemodialysis with hyperuricemia. End stage renal disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient has at least three months of regular hemodialysis history. Patient does not use uric acid-lowering medications. Patient does not use diuretics or ARBs (angiotensin receptor blockers). Patient does not have an acute gout attack. Hyperuricemia: serum uric acid =7 mg/dL in men and =6 mg/dL in women.
Exclusion criteria
Exclusion criteria: Inability to give informed consent. Pregnancy or breastfeeding. Active malignancy undergoing chemo- or radiotherapy. Severe hypersensitivity to allopurinol Use of azathioprine or 6-mercaptopurine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in mean serum total cholesterol level (mg/dL) in patients before and three months after the intervention. Timepoint: Before the intervention (baseline) and three months after the start of the intervention. Method of measurement: For lipid profile variables (total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein), blood biochemical testing using standard laboratory kits is used. For medication adherence behavior, the End-Stage Renal Disease Adherence Questionnaire is used. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in mean serum creatinine level (mg/dL) in patients before and three months after the intervention. Timepoint: Before the intervention (baseline) and three months after the start of the intervention. Method of measurement: For uric acid, creatinine, and albumin, blood testing using standard biochemical kits is performed in the laboratory of Shahid Beheshti Hospital in Hamadan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Hamedan University of Medical Sciences